Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Renee Lichtenstein"'
Autor:
Codruta Chiuzan, Ahmed Sawas, Hye A. Kim, Aishling M. Rada, Mark A. Francescone, Jennifer E Amengual, Laine Atkins, Renee Lichtenstein, Lorenzo Falchi, Lawrence B. Schwartz, Emily Lichtenstein, Changchun Deng, Serge Cremers, Enrica Marchi, Jennifer K. Lue, Matko Kalac, Owen A. O'Connor, Karen Khan
Publikováno v:
Blood. 131:397-407
Peripheral T-cell lymphomas (PTCL) are a group of rare malignancies characterized by chemotherapy resistance and poor prognosis. Romidepsin and pralatrexate were approved by the US Food and Drug Administration for patients with relapsed/refractory PT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff0df60efecae1bb65e5bde675ddf46e
https://doi.org/10.1182/blood-2017-09-806737
https://doi.org/10.1182/blood-2017-09-806737
Autor:
John Kuruvilla, Serge Cremers, Jennifer E Amengual, Celeste Rojas, Michael Crump, Ithamar Turenne, Lorenzo Falchi, Matko Kalac, Anca Prica, Ahmed Sawas, Diego Villa, Joseph M. Connors, Bin Cheng, Owen A. O'Connor, Kerry J. Savage, Lawrence H. Schwartz, Changchun Deng, Jennifer K. Lue, Renee Lichtenstein, Mark A. Francescone, Enrica Marchi, Vishal Kukreti
Publikováno v:
The Lancet. Oncology. 19(2)
Summary Background Brentuximab vedotin is currently approved for patients with relapsed or refractory Hodgkin's lymphoma who previously received an autologous stem cell transplant or two previous multiagent chemotherapy regimens, and for patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0194f65c061f0f326644987a4be9778
https://pubmed.ncbi.nlm.nih.gov/30023401
https://pubmed.ncbi.nlm.nih.gov/30023401
Autor:
Darrell R. Fisher, Qing Liang, Sandy Konerth, Boglarka Gyurkocza, Vijay Reddy, Matthew L. Ulrickson, Jennifer A Spross, Eileen M. Geoghegan, Dale L. Ludwig, Rajneesh Nath, Renee Lichtenstein, Mark S. Berger
Publikováno v:
Blood. 134:1958-1958
Introduction Nearly all adoptive cell therapies currently being evaluated in the clinic, including CAR-T, TIL, and TCR-based cell therapies, require lymphodepletion to remove cellular cytokine sinks and create a favorable cytokine environment for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6598fa46b87c3d0557a3e3dd1ae04032
https://doi.org/10.1182/blood-2019-128838
https://doi.org/10.1182/blood-2019-128838
Autor:
Jennifer A Spross, Benjamin Tomlinson, Boglarka Gyurkocza, Vijay Reddy, Mark S. Berger, Renee Lichtenstein
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S232
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b15a2c18ac1e71a2bbdc25c91054bfc
https://doi.org/10.1016/j.clml.2019.07.117
https://doi.org/10.1016/j.clml.2019.07.117
Autor:
Renee Lichtenstein, Boglarka Gyurkocza, Jennifer A Spross, Vijay Reddy, Ben K. Tomlinson, Mark S. Berger
Publikováno v:
Journal of Clinical Oncology. 37:7048-7048
7048 Background: The SIERRA trial is a prospective, randomized, phase 3, open-label, ongoing multicenter trial for patients aged ≥55 years with active, relapsed/refractory (R/R) AML evaluating allogeneic hematopoietic cell transplantation (HCT) ver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::819305ae56df818e7099702f8b8ab744
https://doi.org/10.1200/jco.2019.37.15_suppl.7048
https://doi.org/10.1200/jco.2019.37.15_suppl.7048
Autor:
Emily Lichtenstein, Jennifer K. Lue, Jennifer E Amengual, Serge Cremers, Laine E. Atkins, Ahmed Sawas, Changchun Deng, Hyea Kim, Karen Khan, Renee Lichtenstein, Owen A. O'Connor, Ithamar Turenne, Codruta Chiuzan, Celeste Rojas
Publikováno v:
Hematological Oncology. 35:87-88
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5b348f31cbe933feb29a7ea6b792681
https://doi.org/10.1002/hon.2437_75
https://doi.org/10.1002/hon.2437_75
Autor:
Celeste Rojas, Emily Lichtenstien, Karen Kahn, Jennifer E Amengual, Ahmed Sawas, Serge Cremers, Renu Nandakumar, Yuxuan Liu, Changhong Qiao, Owen A. O'Connor, Jennifer K. Lue, Changchun Deng, Renee Lichtenstein
Publikováno v:
Blood. 128:1824-1824
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas in which only ~25% of patients experience long-term survival with CHOP chemotherapy. Recently several drugs have been approved for this entity including pralatrexate (P), romidep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::037ab6575349c9c1e2e8116f4057e3b1
https://doi.org/10.1182/blood.v128.22.1824.1824
https://doi.org/10.1182/blood.v128.22.1824.1824
Autor:
Ahmed Sawas, Donald Steven Colbourn, Michael J. Smith, Changchun Deng, Renee Lichtenstein, Emily Lichtenstein, Karen Khan, Owen A. O'Connor, Jennifer E Amengual, Celeste Rojas, Heather Dials
Publikováno v:
Journal of Clinical Oncology. 34:2552-2552
2552Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas in which only 20-25% of patients experience long-term survival with CHOP chemotherapy. Recently several drugs...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d57405397e37305304bf9e8d24a75e4d
https://doi.org/10.1200/jco.2016.34.15_suppl.2552
https://doi.org/10.1200/jco.2016.34.15_suppl.2552
Autor:
Changchun Deng, Renee Lichtenstein, Kelly Zullo, Donald Steven Colbourn, Ahmed Sawas, Jennifer E Amengual, Luigi Scotto, Enrica Marchi, Emily Lichtenstein, Owen A. O'Connor, Michael J. Smith, Celeste Rojas, Ellen Neylon
Publikováno v:
Blood. 126:1282-1282
Introduction: The TCL are chemotherapy resistant neoplasms associated with a poor outcome. Recently, mutations in a number of important genes controlling epigenetic functions have been reported, including mutations in TET2, IDH1/2 and DNMT3. As a cla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a37793d1b1a06163edbf644818861d55
https://doi.org/10.1182/blood.v126.23.1282.1282
https://doi.org/10.1182/blood.v126.23.1282.1282
Autor:
John Kuruvilla, Celeste Rojas, Emily Lichtenstein, Joseph M. Connors, Michael Crump, Jennifer E Amengual, Changchun Deng, Renee Lichtenstein, Ellen Neylon, Owen A. O'Connor, Ahmed Sawas, Diego Villa
Publikováno v:
Blood. 126:586-586
Introduction Patients with HL or ALCL who have relapsed post or are ineligible for autologous stem cell transplant (ASCT) remain incurable with standard therapies. The CD30 immunoconjugate Brentuximab vedotin has become the preferred treatment for su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc4fa024d789e4f5635b1b6d5bddf8fd
https://doi.org/10.1182/blood.v126.23.586.586
https://doi.org/10.1182/blood.v126.23.586.586